西沙比利对功能性消化不良病人胃肠激素的影响

①目的探讨西沙比利对功能性消化不良病人胃肠激素影响.②方法采用放射免疫法测定98例功能性消化不良病人西沙比利治疗前后血浆胃动素、促胃液素、血管活性肠肽和生长抑素水平.③结果西沙比利可使功能性消化不良病人临床症状明显改善(x2=20.22,10.10,P＜0.01),同时血浆中胃动素由(85.2士13.7)pmol/L升高至(131.5±15.6)pmol/L,差异有显著性(t=22.08,P＜0.01).④结论西沙比利可明显改善功能性消化不良病人的临床症状,同时升高血浆中胃动素水平.     

Study on gastric empty disorder after the gastric ulcer healing and therapeutic effect of cisapride

Nonspecific symptoms of ulcer, such as epigastric bloating, early satiety, nausea and anorexia, exist in some patients with gastric ulcer healing, the cause is still nuclear. Gastric emptying inthe patients with continual or recurrent dyspepsiasymptoms after gastric ulcer healing was evaluatedby using real--time ultrasonography. The patientswere treated by several doses of cisapride. Theaims of this study were to evaluate the gastricemptying disorders after gastric ulcer healing andthe therape…     

西沙必利治疗糖尿病性胃轻瘫35例疗效评价

目的 :探讨全胃肠道促动力药物西沙必利对糖尿病性胃轻瘫 (DGP)的治疗作用。方法 :采用胃电图(EGG)体表描记法 ,分别描记DGP患者治疗前后及对照组EGG的数值 ,间接判断DGP患者治疗前后胃排空功能变化。结果 :治疗前DGP与对照组胃体、胃窦部的平均振幅 (AP)、峰值频率 (FP)均存在显著性差异 (P <0 .0 5或P <0 .0 1)。治疗后 2组比较 ,除胃窦AP外 ,胃体AP、FP及胃窦FP均无显著性差异 (P >0 .0 5 ) ,胃轻瘫患者的临床症状也得到显著改善。结论 :西沙必利是治疗DGP的有效药物。     

西沙必利胶囊溶出度测定方法的研究

目的：建立西沙必利胶囊的溶出度测定方法。方法：依照《中国药典》，以盐酸溶液(0．05→1000)500ml为溶出介质，转速为50r／min，分光光度法检测，检测波长为308nm。结果：在5．057～12．136μg／ml范围内(r=0．9998)，浓度与其吸收度呈良好线性关系，平均回收率为99．89％，RSD-0．29％。结论：该方法操作简便，准确可靠。     

2型糖尿病患者胃排空影响因素及西沙必利治疗观察

 [目的]探讨2型糖尿病患者胃排空影响因素、单光子发射计算机断层摄影（SPECT）显影技术和B超在糖尿病性胃轻瘫诊断中的应用及西沙必利治疗效果.[方法]①对120例2型糖尿病进行临床分析.②120例2型糖尿病随机分为两组：A组应用核素^99mTc-SC标记固体试餐,SPECT显像技术检测胃半排空时间（T1/2）;B组予B超检测T1/2.两组均检测空腹血糖（FBG）和糖基化血红蛋白（HbA1c）.③胃T1/2延迟者予西沙必利30 mg,/d,疗程均为1个月,复查胃T1/2.[结果]①糖尿病性胃轻瘫的发生与年龄、病程、空腹血糖、糖基化血红蛋白、神经病变及微血管病变呈正相关（P＜0.01）;②A组60例患者中24例（40.0%）胃T1/2延迟;B组：60例患者中22例（36.7%）.两种检查方法的检出率差异无统计学意义（P＞0.05）;③西沙必利治疗A组有效率为91.7%,B组为90.9%.[结论]糖尿病性胃轻瘫与年龄、病程、高血糖、神经病变及微血管病变相关;SPECT显像技术与B超检出率相似,但不排除与病例数少有关.患者对这两种检查方法耐受性好,但SPECT显像技术费用高,不利于广泛开展,而B超价廉,易于临床使用.西沙必利是有力的促进胃动力的药物,对糖尿病性胃轻瘫有一定的改善胃排空的疗效.     

Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites

BACKGROUND: Spontaneous bacterial peritonitis (SBP) is a serious complication of cirrhosis with ascites, having high recurrence despite antibiotic prophylaxis. Small bowel dysmotility and bacterial overgrowth have been documented to be related to SBP. The purpose of the present paper was (i) to study whether addition of a prokinetic agent to norfloxacin ameliorates the development of SBP in high-risk patients; and (ii) to identify risk factors for SBP development. METHODS: A prospective, single blinded, randomized controlled trial was conducted in high-risk cirrhotic patients with ascites who had either recovered from an episode of SBP or who had low ascitic fluid protein. Norfloxacin 400 mg once daily (group I) or norfloxacin 400 mg once daily with cisapride 20 mg twice a day (group II) was given and occurrence of side-effects of therapy and mortality were recorded. RESULTS: Of the 94 patients, 48 (51%) were in group I, and 46 (49%) in group II. The actuarial probability of developing SBP at 12 month in group I was 56.8% and in group II, 21.7% (P = 0.026). Treatment failure was observed in five patients (10%) in group I and none in group II (P = 0.003). The actuarial probability of death at 18 months was 20.6% in group I and 6.2% in group II (P = 0.1). Low serum albumin, low ascitic fluid protein and alcoholic cirrhosis were related to development of SBP (P < 0.05). Additionally, low serum albumin (2.8 g/dL), gastrointestinal bleeding, alcoholic cirrhosis and low ascitic fluid protein were significantly associated with multiple occurrences of SBP. CONCLUSIONS: Prophylaxis with norfloxacin and cisapride significantly reduces the incidence of SBP in high-risk cirrhosis patients; low serum albumin, low ascitic fluid protein and alcoholic cirrhosis predispose to the development of SBP in high-risk cirrhosis patients; and low ascitic fluid protein should also be considered as a risk factor for the development of SBP requiring prophylaxis.     

西沙必利促慢性肝炎患者胆囊排空的疗效观察

目的：了解西沙必利促进慢性肝病患者胆囊排空情况。方法：超声对比观察22例正常对照者及30例慢性肝病患者空腹胆囊大小及脂肪餐后胆囊收缩情况,对其中16例有胆囊排空障碍的病人,给予西沙必利10mg,3/日治疗四周后复查。结果：正常对照组与慢性肝病组餐前胆囊面积有显著差异,餐后胆囊收缩率也有显著差异,慢性肝炎组存在餐后胆囊排空障碍,16例有排空障碍的慢性肝病患者经西沙必利治疗4周后,胆囊排空有显著改善,结论：慢性肝病患者常伴有胆囊排空运动障碍,西沙必利有改善胆囊排空障碍的作用。     

厚朴排气合剂治疗腹部非胃肠吻合术后早期肠麻痹（气滞证）临床研究

目的观察厚朴排气合剂治疗腹部非胃肠吻合术后早期肠麻痹（气滞证）的临床疗效。方法采用随机对照的原则，将116例本病患者分为治疗组87例，对照组29例，治疗组口服厚朴排气合剂治疗，对照组口服西沙比利片治疗，24h后观察疗效。结果临床综合疗效总有效率治疗组为93．1％，对照组为86．2％，中医症状积分治疗前后差值治疗组为（21．94±7．08），对照组为（19．41±8．76），肛门排气症状改善治疗组平均起效时间为（13．49±4．71）h，对照组为（15．58±5．30）h，2组上述各指标比较，差异均无统计学意义（P〉0．05）。提示厚朴排气合剂对腹部非胃肠吻合术后早期肠麻痹（气滞证）有积极疗效，与西沙比利疗效相近。结论厚朴排气合剂有促进肛门排气，消除腹部胀满，减轻疼痛，以达到改善腹部非胃肠吻合术后早期肠麻痹的作用。     

西沙必利在腹膜氧合治疗急性肺损伤中对血气的影响

目的　探讨西沙必利在腹膜氧合治疗急性肺损伤的过程中,对血气的变化及其可能机制。方法　24只家 兔经油酸诱发急性肺损伤模型后,随机分为腹膜氧合组(A组)、腹膜氧合西沙必利组(B组)和非腹膜氧合西沙必 利组(C组),每组8只,各组在急性肺损伤出现后,观察治疗1、2、4h动脉血气变化。结果　A、B组治疗后各时点 动脉血氧分压(PaO2)进行性升高,C组治疗后各时点动脉血氧分压升高不明显。治疗后1hB组的PaO2明显高于 A、C两组(P<0.05),而A、C两组间无统计意义(P>0.05);在治疗后2、4h两个时点,A、B、C三组间的PaO2均 有显著差异(P<0.05),其中以B组的PaO2最高,A组次之。动脉血二氧化碳分压(PaCO2)各组间没有显著差异 (P>0.05)。结论　在经腹膜氧合治疗急性肺损伤过程中,西沙必利可能通过增加内脏血液循环进一步促进腹膜 氧合的效果,因而可作为腹膜氧合中有益的辅助药物。